| 1 |
34465864 | PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. | 2022 Feb |
1 |
| 2 |
34100216 | Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. | 2021 Jun |
2 |
| 3 |
34523337 | Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. | 2021 Oct 4 |
7 |
| 4 |
32629830 | Chemopreventive Agent 3,3'-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells. | 2020 Jun 30 |
2 |
| 5 |
32806555 | MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. | 2020 Aug 12 |
1 |
| 6 |
30274984 | Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. | 2019 Jan 1 |
1 |
| 7 |
30755442 | MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. | 2019 May 1 |
1 |
| 8 |
31289443 | MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). | 2019 |
1 |
| 9 |
31311404 | MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. | 2019 |
2 |
| 10 |
29857559 | The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. | 2018 May 31 |
5 |
| 11 |
27353420 | Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. | 2016 Jun 28 |
2 |
| 12 |
25832557 | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. | 2015 Aug |
1 |
| 13 |
26998348 | The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. | 2015 |
1 |